Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E15.35 EPS (ttm)21.02 Insider Own0.10% Shs Outstand207.82M Perf Week-0.04%
Market Cap67.04B Forward P/E11.56 EPS next Y27.91 Insider Trans-0.48% Shs Float200.66M Perf Month-0.80%
Income4.36B PEG1.96 EPS next Q6.72 Inst Own91.10% Short Float1.84% Perf Quarter-5.12%
Sales13.23B P/S5.07 EPS this Y3.00% Inst Trans-0.65% Short Ratio2.84 Perf Half Y5.12%
Book/sh68.35 P/B4.72 EPS next Y8.06% ROA12.90% Target Price388.35 Perf Year-1.65%
Cash/sh21.31 P/C15.14 EPS next 5Y7.85% ROE24.20% 52W Range249.17 - 388.67 Perf YTD1.27%
Dividend- P/FCF11.54 EPS past 5Y24.80% ROI21.90% 52W High-17.00% Beta0.98
Dividend %- Quick Ratio2.50 Sales past 5Y17.30% Gross Margin86.10% 52W Low29.47% ATR9.54
Employees7300 Current Ratio2.70 Sales Q/Q11.70% Oper. Margin44.70% RSI (14)49.03 Volatility3.36% 2.98%
OptionableYes Debt/Eq0.43 EPS Q/Q23.60% Profit Margin24.10% Rel Volume1.03 Prev Close322.61
ShortableYes LT Debt/Eq0.43 EarningsJan 22 BMO Payout0.00% Avg Volume1.30M Price322.61
Recom2.00 SMA200.05% SMA50-0.32% SMA2003.44% Volume0 Change0.00%
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Aug-07-18Resumed Stifel Buy $394
Jul-25-18Reiterated SunTrust Buy $321 → $392
Jul-10-18Downgrade Robert W. Baird Outperform → Neutral
Jul-06-18Upgrade Citigroup Neutral → Buy
May-31-18Upgrade Canaccord Genuity Hold → Buy $350 → $335
Apr-25-18Upgrade Robert W. Baird Neutral → Outperform
Apr-05-18Downgrade Barclays Overweight → Equal Weight $395 → $295
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Oct-24-17Initiated Guggenheim Buy $402
Dec-12-18 10:51AM  5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 InvestorPlace
10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
Dec-06-18 07:30AM  Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data GlobeNewswire
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 09:00AM  AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018 Zacks
Nov-30-18 04:16PM  Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar Investor's Business Daily
Nov-29-18 11:45AM  How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big Investor's Business Daily
10:11AM  Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma Zacks
07:30AM  International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product GlobeNewswire
Nov-27-18 05:33PM  Health Care Stocks May Be Safe Haven in Event of Market Downturn GuruFocus.com
Nov-26-18 04:18PM  Hedge Funds Are Crazy About Biogen Inc. (NASDAQ:BIIB) Insider Monkey
Nov-23-18 11:11AM  US benefits manager baulks after Novartis values gene therapy at $4-5 mln Reuters
08:26AM  Why Biogen Inc (NASDAQ:BIIB) Looks Like A Quality Company Simply Wall St.
01:05AM  U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million Reuters
Nov-22-18 09:30AM  Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report? Zacks
Nov-21-18 09:47AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-14-18 03:09PM  Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels MarketWatch
06:11AM  [$$] Possible delisting of BioLogics threatens Samsungs growth strategy Financial Times
Nov-13-18 03:35PM  An expensive new medication is finally available for her rare disease but shes been fighting for two years to get it MarketWatch
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace
12:50PM  Ionis Pharmaceuticals Collects Royalties -- and Spends It All Motley Fool
Nov-09-18 11:02AM  6 Pharmaceutical Stocks to Buy After the Midterms InvestorPlace
Nov-08-18 04:11PM  Jeff Auxier Comments on Biogen GuruFocus.com
03:45PM  Jeff Auxier's Auxier Asset Management 3rd Quarter Commentary GuruFocus.com
Nov-07-18 03:43PM  7 Healthcare Stocks Soaring on Election Results InvestorPlace
Nov-06-18 05:48PM  Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool
Nov-05-18 02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
Nov-02-18 02:23PM  AbbVie sees hit to Humira sales from European competition Reuters
06:57AM  Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More Benzinga
Nov-01-18 03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks
Oct-31-18 01:11PM  Sarissa Capitals Alex Denner Bullish on Biogen (BIIB) Insider Monkey
Oct-29-18 04:16PM  Biogen And Eisai May Be At Odds In Alzheimer's So What Now? Investor's Business Daily
08:20AM  New Research Coverage Highlights Rite Aid, The Boeing, Cabot, Biogen, McDonald's, and Pegasystems Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-28-18 09:56PM  Clearbridge Investments Betting On A Shift From Growth and Momentum Insider Monkey
12:31PM  This experimental Alzheimers disease drug seemed promising before the latest results left many unsure MarketWatch
Oct-26-18 11:55AM  The October stock crash has wiped out $45.5B from Mass. health firms American City Business Journals
10:45AM  Top Research Reports for McDonald's, Thermo Fisher & Caterpillar Zacks
09:15AM  Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimers Disease (CTAD) GlobeNewswire
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
Oct-25-18 04:07PM  Biogen Stock Dips After Alzheimer's Results Show 'Thin' Impact Investor's Business Daily
01:12PM  Eisai, Biogen Alzheimer's data fails to convince skeptics Reuters
11:01AM  Biogen analysts pounce on 'thin' Alzheimer's trial data American City Business Journals
10:51AM  Biogen shares slip after Alzheimer's data fails to convince Reuters
09:03AM  Biogen/Eisai Alzheimer's data suggests treatment effect related to drug Reuters
08:31AM  Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimers Disease at the 2018 Clinical Trials on Alzheimers Disease (CTAD) Conference GlobeNewswire
08:03AM  The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price Benzinga
Oct-24-18 03:07PM  Biogen Rides the Spinraza Wave to Double-Digit Growth Motley Fool
01:46PM  Alkermes Makes Financial Progress as Its Pipeline Moves Forward Motley Fool
11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks
11:11AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
10:53AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
10:20AM  Forward Pharma loses appeal in Tecfidera patent dispute with Biogen Reuters
02:45AM  Edited Transcript of BIIB earnings conference call or presentation 23-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
Oct-23-18 04:51PM  Biogen Tops Quarterly Views, But Shares Hamstrung On Pipeline 'Stumbles' Investor's Business Daily
03:17PM  Biogen Inc (BIIB) Q3 2018 Earnings Conference Call Transcript Motley Fool
11:38AM  Biogen Earnings: 10 Highlights From BIIBs Q3 InvestorPlace
11:35AM  Stocks - Caterpillar, 3M Tank in Pre-market; McDonalds, Verizon Gain Investing.com
11:32AM  Biogen's Spinraza drives third-quarter profit beat Reuters
11:03AM  Biogen's Spinraza drives third-quarter profit beat Reuters
10:12AM  Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines Zacks
09:49AM  Biogen stock rises 3% after Q3 profit and revenue beats MarketWatch
09:38AM  Biogen Inc Earnings, Revenue beat in Q3 Investing.com
08:29AM  Biogen (BIIB) Q3 Earnings & Sales Beat Estimates Zacks
07:34AM  [$$] Biogen 3Q Profit Rises 18% The Wall Street Journal
06:49AM  Biogen, UCB study of lupus treatment fails primary endpoint MarketWatch
06:37AM  Biogen third-quarter profit rises 17.8 pct Reuters
06:01AM  Stoke CEO weighs clinical trials, IPO and partnerships after $90M round American City Business Journals
01:00AM  UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus GlobeNewswire
Oct-22-18 03:13PM  Biogen earnings: Its all about upcoming Alzheimers disease results MarketWatch
02:39PM  Biogen Q3 Earnings Outlook Benzinga
12:35PM  Analysts wary of Biogen's strategy as earnings, Alzheimer's data loom American City Business Journals
10:32AM  BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store? Zacks
06:00AM  Biogen on Deck as Biotechs Face Make-or-Break Earnings Season Bloomberg
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
08:49AM  Better Buy: Biogen Inc. vs. Amgen Inc. Motley Fool
Oct-19-18 04:28PM  Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards? Zacks
09:38AM  Alkermes Boasts Strong Portfolio and Impressive Pipeline Zacks
07:43AM  Stocks making the biggest move premarket: PG, HON, F, VFC, HOG AMZN & more CNBC
Oct-18-18 07:30AM  Biogen to Present Data from Alzheimers Disease Portfolio at the 2018 Clinical Trials on Alzheimers Disease (CTAD) Meeting GlobeNewswire
Oct-17-18 10:47AM  MIT researchers among winners of prestigious Breakthrough Prize American City Business Journals
03:47AM  Samsung launches third rival to AbbVie's Humira drug in EU Reuters
02:18AM  Biogen and Samsung Bioepis Announce European Launch of IMRALDI(adalimumab), Solidifying Leadership in European Anti-TNF Market Business Wire
02:00AM  IMRALDI, Biogens Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union GlobeNewswire
Oct-11-18 08:21AM  The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC Zacks
07:30AM  Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis GlobeNewswire
Oct-10-18 02:12PM  Top Analyst Reports for Altria, U.S. Bancorp & Biogen Zacks
10:18AM  Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status Zacks
Oct-08-18 04:05PM  Best Mutual Funds Buying CVS, Biogen, Lowe's And These Other Top Stocks Investor's Business Daily
Oct-06-18 07:30AM  New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy GlobeNewswire
Oct-05-18 06:15AM  Ex-Biogen employee with Parkinson's sues for discrimination American City Business Journals
Oct-04-18 07:32AM  PRESS DIGEST- Canada - Oct. 4 Reuters
Oct-03-18 07:30AM  Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinsons Disease and Movement Disorders (MDS) GlobeNewswire
02:06AM  With Hemlibra, Roche seeks to break into tight hemophilia circle Reuters
Oct-02-18 01:00PM  6 Health Care Stocks Poised For Healthy Gains Investopedia
07:30AM  Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care GlobeNewswire
Sep-28-18 01:44PM  Health care is having its best quarter in five years, and one winner is set to keep surging CNBC
Sep-26-18 02:11PM  US STOCKS-Wall Street extends gains after Fed rate hike Reuters
Sep-24-18 04:06PM  Can Biogen Continue to Be a Top Performer in the Biotech Space? GuruFocus.com
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0053204,539Mar 05 04:41 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 27Sale290.8325975,3256,553Feb 28 05:39 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Option Exercise0.0046707,020Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.009204,772Feb 27 06:24 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 23Option Exercise0.00857025,225Feb 27 06:22 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Sale293.44908266,4446,553Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 22Option Exercise0.0019404,738Feb 26 04:11 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,63508,188Feb 26 04:12 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 22Option Exercise0.001,635025,095Feb 26 04:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,354010,233Feb 20 04:27 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,33909,186Feb 20 04:25 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,47204,854Feb 20 04:23 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,71205,407Feb 20 04:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 15Option Exercise0.0016104,600Feb 20 04:18 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 15Option Exercise0.001,712023,970Feb 20 04:17 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Sale298.851,294386,7127,296Feb 20 08:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.002,01208,565Feb 14 06:37 PM
PANGIA ROBERT WDirectorJan 09Option Exercise57.835,832337,26523,539Jan 10 05:28 PM
PANGIA ROBERT WDirectorJan 09Sale329.655,8321,922,51917,707Jan 10 05:28 PM
Vounatsos MichelChief Executive OfficerDec 29Buy320.55780250,0294,879Jan 02 04:21 PM